Science and Research

A Phase III, Double-blind, Rand, Placebo-Controlled Multi-Centre, study to assess the efficacy and safety of AZD 9291 vs. Placebo, in Patients with EGFRr Mut. Positive Stage IB-IIIA NSCLC, following Complete Tumour Reection with or without adj. Chemother.

To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy

Study details
Study-ID: NCT02511106, 2015-000662-65
Study-ID: NCT02511106, 2015-000662-65
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN
DZL Participating Sites: ARCN
Start Date: 21.10.2015
Completion Date: 31.01.2029
Status: Active / not recruiting
Status: Active / not recruiting
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.